Clinical trial
An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy
NCT01316458 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2003
- Completion date
- Not reported
- Enrollment
- 51 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.
antineoplastic agents, genital diseases, male, genital neoplasms, male, imatinib, neoplasms, abdominal, prostatic diseases, prostatic neoplasm, urogenital neoplasms